Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of cervical cancer (adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma), confirmed through laboratory testing of tissue
- People with early-stage cervical cancer classified as FIGO stage IA2, IB1, or IB2, with a tumour smaller than 4 cm
- People who are planned to have a radical hysterectomy (surgical removal of the uterus and surrounding tissue), or in some low-risk cases, a simpler type of hysterectomy where the tumour is smaller than 2 cm and meets certain depth criteria (confirm with trial site)
- People with a general health and activity level rated as ECOG 0 or 1, meaning they are fully active or have only minor limitations in daily activities
- People who are considered medically suitable for surgery, have had a pre-operative MRI scan, and are able to attend follow-up appointments for up to one year after surgery
- People who have read and signed an approved consent form agreeing to take part
- People who have had a previous cancer, only if it was more than 5 years ago and there is no current sign of that cancer returning
- Females aged 18 years or older
Who may not be able to join:
- People whose cervical cancer is of a different tissue type than those listed above
- People whose tumour is 4 cm or larger, as measured by MRI or physical examination
- People with more advanced cervical cancer, classified as FIGO stage IB3 or higher
- People who have previously had radiation therapy to the pelvis or abdomen
- People whose cancer has spread to other parts of the body, or who have significantly enlarged lymph nodes or lymph nodes that have tested positive for cancer
- People with serious ongoing health conditions that the trial investigators determine would make participation unsafe
- People who are unable to be positioned in the specific surgical positions required for the operation (confirm with trial site)
- People who are unlikely to be able to attend the required follow-up appointments, or who live too far from the trial site
- People who are currently pregnant
- People for whom surgery is not considered safe or appropriate
- People who have been diagnosed with another invasive cancer within the last 5 years (exceptions may apply for certain low-risk skin cancers or specific early-stage breast cancers — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Hillemanns, Prof. Dr., Hannover Medical School, Department of Gynecology and Obstetrics
Phone: +49 (0) 511 532
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.